Crossmark Global Holdings Inc. Sells 88 Shares of Masimo Co. (NASDAQ:MASI)

Crossmark Global Holdings Inc. cut its holdings in Masimo Co. (NASDAQ:MASI) by 2.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,160 shares of the medical equipment provider’s stock after selling 88 shares during the period. Crossmark Global Holdings Inc.’s holdings in Masimo were worth $522,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. NBC Securities Inc. grew its position in Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 73 shares during the last quarter. MML Investors Services LLC grew its position in Masimo by 4.9% during the third quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider’s stock worth $274,000 after buying an additional 96 shares in the last quarter. UMB Bank n.a. increased its stake in Masimo by 180.9% during the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 123 shares during the period. Assetmark Inc. raised its holdings in Masimo by 12.7% in the 3rd quarter. Assetmark Inc. now owns 1,183 shares of the medical equipment provider’s stock valued at $158,000 after acquiring an additional 133 shares in the last quarter. Finally, Nordea Investment Management AB lifted its position in shares of Masimo by 0.7% in the 4th quarter. Nordea Investment Management AB now owns 19,182 shares of the medical equipment provider’s stock worth $3,206,000 after acquiring an additional 142 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Stock Up 1.3 %

MASI opened at $170.24 on Monday. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $180.97. The firm has a market cap of $9.11 billion, a price-to-earnings ratio of 117.41 and a beta of 1.01. The firm’s 50-day simple moving average is $170.32 and its 200-day simple moving average is $142.65. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.14. The firm had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.63 earnings per share. Equities research analysts anticipate that Masimo Co. will post 4.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on MASI. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday, January 22nd. Wells Fargo & Company boosted their price target on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Piper Sandler raised their price objective on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Stifel Nicolaus reiterated a “buy” rating and set a $190.00 target price (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Finally, Raymond James increased their price target on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $179.67.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.